Matches in UGent Biblio for { <https://biblio.ugent.be/publication/1048644#aggregation> ?p ?o. }
Showing items 1 to 30 of
30
with 100 items per page.
- aggregation classification "C3".
- aggregation creator B71488.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2010".
- aggregation hasFormat 1048644.bibtex.
- aggregation hasFormat 1048644.csv.
- aggregation hasFormat 1048644.dc.
- aggregation hasFormat 1048644.didl.
- aggregation hasFormat 1048644.doc.
- aggregation hasFormat 1048644.json.
- aggregation hasFormat 1048644.mets.
- aggregation hasFormat 1048644.mods.
- aggregation hasFormat 1048644.rdf.
- aggregation hasFormat 1048644.ris.
- aggregation hasFormat 1048644.txt.
- aggregation hasFormat 1048644.xls.
- aggregation hasFormat 1048644.yaml.
- aggregation language "eng".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Optimized alkylated cyclodextrin polysulphates restore osteoarthritic chondrocyte extracellular matrix metabolism".
- aggregation abstract "Purpose: To compare the ability of different cyclodextrin polysulphate derivatives to affect human articular cartilage cell metabolism in vitro and to act as Disease Modifying OsteoArthritis Drugs in vivo. Methods and Materials: OA chondrocytes were cultured in gelled alginate and exposed to 5 μg/ml (2-carboxyethyl)-β-cyclodextrin polysulphate (CE-CDPS), or β-cyclodextrin polysulphate (CDPS) during 5 days. Effects on IL-1-driven chondrocyte extracellular matrix (ECM) metabolism was assayed by analysis of the accumulation of aggrecan in the interterritorial matrix and by the release of IL-6 in the culture supernatant. The compounds were analyzed for their in vitro effect on coagulation and their ability to activate platelets in an in vitro assay to detect possible crossreactivity with HIT (heparin-induced thrombocytopenia) antibodies. CE-CDPS was selected for further qPCR analyses, in order to investigate whether this compound directly influences the gene expression of IL-6 and aggrecan. The effectiveness of CE-CDPS was further assayed in collagenase-induced OA of the knee, by injecting 1 mg/kg CE-CDPS or saline subcutaneously once weekly in a mouse model. Knee joints were scored semiquantitatively on inflammation, fibrosis, osteophyte growth and loss of articular cartilage and Safranin-O staining. Results: The polysulphated cyclodextrin CE-CDPS at 5 μg/ml concentrations, significantly induced aggrecan production and repressed IL-6 release by the chondrocytes in culture. Five μg/ml of CE-CDPS, in contrast to other polysulphated cyclodextrins, did not significantly activate platelets and thus showed no potential to induce HIT thromboembolic accidents in vivo. Therefore, CE-CDPS was selected for further qPCR analyses. These analyses confirmed the anabolic and anti-catabolic profile of CE-CDPS. CE-CDPS was therefore tested on collagenase–induced knee OA in mice and was shown to prevent cartilage proteoglycan depletion but not osteophyte formation in the OA knee joints of these mice. Conclusions: CE-CDPS is a new, structurally adjusted sulphated β-cyclodextrin derivative with preserved chondroprotective capacity and a promising safety profile.".
- aggregation authorList BK182059.
- aggregation isDescribedBy 1048644.
- aggregation similarTo LU-1048644.